Back to News
Market Impact: 0.25
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Fresenius secured exclusive option rights for up to 37 potential first-to-market biosimilar candidates. If developed, these could expand its marketed and pipeline portfolio from 29 molecules to as many as 66 over the next decade, targeting originator products with more than €370 billion in sales.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead